Harnessing synthetic lethal interactions in anticancer drug discovery
Denise A. Chan,Amato J. Giaccia +1 more
Reads0
Chats0
TLDR
Strategies that can be used to identify synthetic lethal interactions for anticancer drug discovery are summarized, examples of such interactions that are currently being investigated in preclinical and clinical studies of targeted anticancer therapies are described, and the challenges of realizing the full potential of such therapies are discussed.Abstract:
Unique features of tumours that can be exploited by targeted therapies are a key focus of current cancer research. One such approach is known as synthetic lethality screening, which involves searching for genetic interactions of two mutations whereby the presence of either mutation alone has no effect on cell viability but the combination of the two mutations results in cell death. The presence of one of these mutations in cancer cells but not in normal cells can therefore create opportunities to selectively kill cancer cells by mimicking the effect of the second genetic mutation with targeted therapy. Here, we summarize strategies that can be used to identify synthetic lethal interactions for anticancer drug discovery, describe examples of such interactions that are currently being investigated in preclinical and clinical studies of targeted anticancer therapies, and discuss the challenges of realizing the full potential of such therapies.read more
Citations
More filters
Journal ArticleDOI
The NAD metabolome — a key determinant of cancer cell biology
TL;DR: Given that NAD+-dependent signalling reactions involve the degradation of the molecule, permanent nucleotide resynthesis through different biosynthetic pathways is crucial for incessant cancer cell proliferation, this necessity supports the targeting of NAD metabolism as a new therapeutic concept for cancer treatment.
Journal ArticleDOI
Phenotypic screening in cancer drug discovery — past, present and future
TL;DR: It is postulate that the contribution of phenotypic screening to cancer drug discovery has been hampered by a reliance on 'classical' nonspecific drug effects such as cytotoxicity and mitotic arrest, exacerbated by a paucity of mechanistically defined cellular models for therapeutically translatable cancer phenotypes.
Journal ArticleDOI
Target Identification for Small Bioactive Molecules: Finding the Needle in the Haystack
TL;DR: Current methods for target identification of small molecules are summarized, primarily for a chemistry audience but also the biological community, for example, the chemist or biologist attempting to identify the target of a given bioactive compound.
Journal ArticleDOI
Deubiquitinases in cancer: new functions and therapeutic options
TL;DR: Understanding of the physiological regulatory mechanisms of these enzymes may provide answers to multiple remaining questions on DUB functions and lead to the development of DUB-targeting strategies to expand the repertoire of molecular therapies against cancer.
Journal ArticleDOI
Recurrent mutations in multiple components of the cohesin complex in myeloid neoplasms
Ayana Kon,Lee Yung Shih,Masashi Minamino,Masashi Sanada,Masashi Sanada,Yuichi Shiraishi,Yasunobu Nagata,Kenichi Yoshida,Yusuke Okuno,Masashige Bando,Ryuichiro Nakato,Shumpei Ishikawa,Shumpei Ishikawa,Aiko Sato-Otsubo,Genta Nagae,Aiko Nishimoto,Claudia Haferlach,Daniel Nowak,Yusuke Sato,Tamara Alpermann,Masao Nagasaki,Teppei Shimamura,Hiroko Tanaka,Kenichi Chiba,Ryo Yamamoto,Tomoyuki Yamaguchi,Makoto Otsu,Naoshi Obara,Mamiko Sakata-Yanagimoto,Tsuyoshi Nakamaki,Ken Ishiyama,Florian Nolte,Wolf-Karsten Hofmann,Shuichi Miyawaki,Shigeru Chiba,Hiraku Mori,Hiromitsu Nakauchi,H. Phillip Koeffler,H. Phillip Koeffler,Hiroyuki Aburatani,Torsten Haferlach,Katsuhiko Shirahige,Satoru Miyano,Seishi Ogawa,Seishi Ogawa +44 more
TL;DR: A role for compromised cohesin functions in myeloid leukemogenesis is suggested by the growth of leukemic cell lines harboring a mutation in RAD21 or having severely reduced expression of RAD21 and STAG2 being suppressed by forced expression of wild-type RAD21 (Kasumi-1 cells and MOLM-13 cells).
References
More filters
Journal ArticleDOI
Sorafenib in Advanced Hepatocellular Carcinoma
Josep M. Llovet,Sergio Ricci,Vincenzo Mazzaferro,Philip Hilgard,Edward Gane,Jean-Frédéric Blanc,André Cosme de Oliveira,Armando Santoro,Jean-Luc Raoul,Alejandro Forner,Myron Schwartz,Camillo Porta,Stefan Zeuzem,Luigi Bolondi,Tim F. Greten,Peter R. Galle,Jean Francois Seitz,Ivan Borbath,Dieter Häussinger,Tom Giannaris,Minghua Shan,M. Moscovici,D. Voliotis,Jordi Bruix +23 more
TL;DR: In patients with advanced hepatocellular carcinoma, median survival and the time to radiologic progression were nearly 3 months longer for patients treated with sorafenib than for those given placebo.
Journal ArticleDOI
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
Tony Mok,Yi-Long Wu,Sumitra Thongprasert,Chih-Hsin Yang,Da Tong Chu,Nagahiro Saijo,Patrapim Sunpaweravong,Baohui Han,Benjamin Margono,Benjamin Margono,Yukito Ichinose,Yutaka Nishiwaki,Yuichiro Ohe,Jin Ji Yang,Busyamas Chewaskulyong,Haiyi Jiang,Emma Duffield,Claire Watkins,Alison Armour,Masahiro Fukuoka +19 more
TL;DR: Gefit inib is superior to carboplatin-paclitaxel as an initial treatment for pulmonary adenocarcinoma among nonsmokers or former light smokers in East Asia and the presence in the tumor of a mutation of the EGFR gene is a strong predictor of a better outcome with gefitinib.
Journal ArticleDOI
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Hannah Farmer,Nuala McCabe,Christopher J. Lord,Andrew Tutt,Andrew Tutt,Damian A. Johnson,Tobias B. Richardson,Manuela Santarosa,Krystyna J. Dillon,Ian Hickson,Charlotte Knights,Niall M. B. Martin,Stephen P. Jackson,Graeme C. M. Smith,Alan Ashworth +14 more
TL;DR: BRCA1 or BRCA2 dysfunction unexpectedly and profoundly sensitizes cells to the inhibition of PARP enzymatic activity, resulting in chromosomal instability, cell cycle arrest and subsequent apoptosis, illustrating how different pathways cooperate to repair damage.
Journal ArticleDOI
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.
Robert J. Motzer,Thomas E. Hutson,Piotr Tomczak,M. Dror Michaelson,Ronald M. Bukowski,Olivier Rixe,Stéphane Oudard,Sylvie Negrier,Cezary Szczylik,Sindy T. Kim,Isan Chen,Paul Bycott,Charles M. Baum,Robert A. Figlin +13 more
TL;DR: Progression-free survival was longer and response rates were higher in patients with metastatic renal-cell cancer who received sunitinib than in those receiving interferon alfa.